<p>Vivos Therapeutics Inc. reported significant revenue growth for the third quarter of 2025, with a 78% sequential quarter-over-quarter increase and a 76% rise compared to the same period in the previous year. The company attributed the growth to its strategic shift from relying on a dental industry distribution channel to acquiring and affiliating with medical sleep practices and testing centers, highlighted by the June 2025 acquisition of The Sleep Center of Nevada. Further details and financial results for the three and nine months ended September 30, 2025, are available in the company’s Quarterly Report on Form 10-Q filed with the SEC. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-024289), on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

VVOS

<p>Vivos Therapeutics Inc. reported a 78% sequential revenue growth in Q3 2025, with a 76% increase year-over-year. This growth is attributed to a strategic shift from dental industry distribution to acquiring medical sleep practices, highlighted by acquiring The Sleep Center of Nevada in June 2025. Detailed financial results are available in their Form 10-Q filed with the SEC.</p>

Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025